Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891640283> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2891640283 abstract "e22509 Background: In controlled trials that allow patients to crossover from placebo (PBO) to active treatment (ACT) after progression, OS in PBO patients is confounded by ACT. Statistical methods to adjust OS for crossover rely on an assumption of common treatment effect (i.e. PBO to ACT crossover after progression has the same impact as ACT started at randomization). This exploratory analysis of two phase 3 trials (PBO-controlled and allowing crossover) with regorafenib in GIST and sorafenib in thyroid cancer provides evidence to support this assumption. Methods: Target lesions were assessed at baseline and at regular intervals post baseline. Progression-free survival (PFS) was assessed during double-blind (DB) treatment and secondary PFS (SPFS) in PBO patients during open-label (OL) treatment. Changes in target lesion diameter over time were estimated by a parametric model. Early tumor growth rate (TGR), defined as percent change from baseline/month in the sum of target lesion diameters, was calculated as the model curve slope at earliest time on the TGR curve. Results: SPFS during OL in PBO patients is closer to DB PFS in ACT patients than to DB PFS in PBO patients (Table). Early TGR during OL in PBO patients is closer to DB early TGR in ACT patients than to DB early TGR in PBO patients. Conclusions: Currently available statistical methods to adjust for the impact of treatment crossover are supported by clinical results from two independent randomized, controlled phase 3 studies. These results provide validity to crossover correction analyses. Clinical trial information: NCT01271712; NCT00984282. [Table: see text]" @default.
- W2891640283 created "2018-09-27" @default.
- W2891640283 creator A5009392187 @default.
- W2891640283 creator A5017931241 @default.
- W2891640283 creator A5027342364 @default.
- W2891640283 creator A5044427863 @default.
- W2891640283 creator A5060580923 @default.
- W2891640283 creator A5080158579 @default.
- W2891640283 date "2017-05-20" @default.
- W2891640283 modified "2023-10-03" @default.
- W2891640283 title "Clinical evidence from two phase 3 trials supporting statistical adjustment methods to assess confounding impact of treatment crossover on overall survival (OS)." @default.
- W2891640283 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e22509" @default.
- W2891640283 hasPublicationYear "2017" @default.
- W2891640283 type Work @default.
- W2891640283 sameAs 2891640283 @default.
- W2891640283 citedByCount "0" @default.
- W2891640283 crossrefType "journal-article" @default.
- W2891640283 hasAuthorship W2891640283A5009392187 @default.
- W2891640283 hasAuthorship W2891640283A5017931241 @default.
- W2891640283 hasAuthorship W2891640283A5027342364 @default.
- W2891640283 hasAuthorship W2891640283A5044427863 @default.
- W2891640283 hasAuthorship W2891640283A5060580923 @default.
- W2891640283 hasAuthorship W2891640283A5080158579 @default.
- W2891640283 hasConcept C122507166 @default.
- W2891640283 hasConcept C126322002 @default.
- W2891640283 hasConcept C142724271 @default.
- W2891640283 hasConcept C143998085 @default.
- W2891640283 hasConcept C154945302 @default.
- W2891640283 hasConcept C177713679 @default.
- W2891640283 hasConcept C204787440 @default.
- W2891640283 hasConcept C27081682 @default.
- W2891640283 hasConcept C41008148 @default.
- W2891640283 hasConcept C535046627 @default.
- W2891640283 hasConcept C71924100 @default.
- W2891640283 hasConcept C77350462 @default.
- W2891640283 hasConcept C87813604 @default.
- W2891640283 hasConceptScore W2891640283C122507166 @default.
- W2891640283 hasConceptScore W2891640283C126322002 @default.
- W2891640283 hasConceptScore W2891640283C142724271 @default.
- W2891640283 hasConceptScore W2891640283C143998085 @default.
- W2891640283 hasConceptScore W2891640283C154945302 @default.
- W2891640283 hasConceptScore W2891640283C177713679 @default.
- W2891640283 hasConceptScore W2891640283C204787440 @default.
- W2891640283 hasConceptScore W2891640283C27081682 @default.
- W2891640283 hasConceptScore W2891640283C41008148 @default.
- W2891640283 hasConceptScore W2891640283C535046627 @default.
- W2891640283 hasConceptScore W2891640283C71924100 @default.
- W2891640283 hasConceptScore W2891640283C77350462 @default.
- W2891640283 hasConceptScore W2891640283C87813604 @default.
- W2891640283 hasLocation W28916402831 @default.
- W2891640283 hasOpenAccess W2891640283 @default.
- W2891640283 hasPrimaryLocation W28916402831 @default.
- W2891640283 hasRelatedWork W1518120855 @default.
- W2891640283 hasRelatedWork W1962218896 @default.
- W2891640283 hasRelatedWork W1968593921 @default.
- W2891640283 hasRelatedWork W1974998390 @default.
- W2891640283 hasRelatedWork W2105906988 @default.
- W2891640283 hasRelatedWork W2120419234 @default.
- W2891640283 hasRelatedWork W2552414929 @default.
- W2891640283 hasRelatedWork W2563902300 @default.
- W2891640283 hasRelatedWork W2583377090 @default.
- W2891640283 hasRelatedWork W2616160160 @default.
- W2891640283 hasRelatedWork W2735966375 @default.
- W2891640283 hasRelatedWork W2757470630 @default.
- W2891640283 hasRelatedWork W2788831685 @default.
- W2891640283 hasRelatedWork W2791551980 @default.
- W2891640283 hasRelatedWork W2890695763 @default.
- W2891640283 hasRelatedWork W3005102142 @default.
- W2891640283 hasRelatedWork W3006459164 @default.
- W2891640283 hasRelatedWork W3016467330 @default.
- W2891640283 hasRelatedWork W3200483052 @default.
- W2891640283 hasRelatedWork W3214187946 @default.
- W2891640283 isParatext "false" @default.
- W2891640283 isRetracted "false" @default.
- W2891640283 magId "2891640283" @default.
- W2891640283 workType "article" @default.